5-bromo-(4-chlorophenoxy)pyridine | 28231-69-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-bromo-(4-chlorophenoxy)pyridine
• 英文别名: 5-bromo-2-(4-chlorophenoxy)pyridine；2-(4-Chlorphenoxy)-5-brompyridin
• CAS: 28231-69-8
• 化学式: C₁₁H₇BrClNO
• 分子量: 284.54
• InChiKey: BJZWAZIZGZLNHA-UHFFFAOYSA-N

物化性质

• 沸点：
  339.9±27.0 °C(Predicted)
• 密度：
  1.568±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4(S)-(3-trifluoromethyl-phenyl)-oxazolidin-2-one 、 5-bromo-(4-chlorophenoxy)pyridine 生成 (S)-3-[6-(4-chloro-phenoxy)-pyridin-3-yl]-4-(3-trifluoromethyl-phenyl)-oxazolidin-2-one
  参考文献：
  名称：

  Compounds and compositions as inhibitors of cannabinoid receptor 1 activity

  摘要：

  本发明提供了化合物、包含这些化合物的药物组合物以及使用这些化合物治疗或预防与大麻素受体1（CB1）的活性相关的疾病或紊乱的方法。

  公开号：

  US08431607B2
• 作为产物：
  描述：

  2,5-二溴吡啶 、 对氯苯酚 在 copper(l) iodide 、 四甲基乙二胺 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以92%的产率得到5-bromo-(4-chlorophenoxy)pyridine
  参考文献：
  名称：

  Copper-catalyzed highly regioselective 2-aryloxylation of 2,x-dihalopyridines

  摘要：

  2,x-Dihalopyridines reacted with phenols catalyzed by CuI/TMEDA in the presence of Cs2CO3 in DMSO at 110 degrees C under nitrogen atmosphere for 24 h to afford 2-aryloxypyridines in good to high yields except p-nitrophenol. To expand this methodology, a vanilloid receptor ligand used in treatments was prepared in good yield. This method has potential utility in the synthesis of pharmaceuticals, agrochemicals and even natural products. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.10.025

文献信息

• [EN] 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS<br/>[FR] COMPOSÉS 4,4A,5,7,8,8 A-HEXAPYRIDO [4,3-B] [1,4] OXAZIN-3-ONE EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021048242A1

  公开（公告）日：2021-03-18

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as monoacylglycerol lipase (MAGL) inhibitors.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、B、L1、X、m、n以及R1到R7如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及将这些化合物用作单酰基甘油酶（MAGL）抑制剂的方法。
• COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
  申请人：Liu Hong

  公开号：US20100234365A1

  公开（公告）日：2010-09-16

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

  本发明提供了化合物、包含这些化合物的制药组合物以及使用这些化合物治疗或预防与大麻素受体1（CB1）活性相关的疾病或障碍的方法。
• SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF
  申请人：Hangzhou Hertz Pharmaceutical Co., Ltd.

  公开号：EP3543239A1

  公开（公告）日：2019-09-25

  The present invention relates to a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, preparation and use thereof in preparation of a drug for treating diseases, disorders or conditions benefiting from the inhibition of Bruton's tyrosine kinase activity. The compound of the present invention has anti-proliferation and inhibitory effects on tumor cell strains such as A549, MINO, OCI-LY10 and TMD-8, and shows an excellent anti-tumor activity in tumor models such as Mino subcutaneous xenografts, and can be applied in drugs for treating solid tumors or leukemia associated with cell proliferation in humans or animals. The compound of the present invention has good pharmacokinetic properties, and can be applied to the oral treatment of solid tumors or leukemia associated with the cell proliferation in humans or animals or autoimmune diseases. The compound of the present invention has the property of a low hERG channel blockade.

  本发明涉及一种选择性布鲁顿酪氨酸激酶（BTK）抑制剂化合物、药物组合物、制剂及其在制备用于治疗受益于抑制布鲁顿酪氨酸激酶活性的疾病、失调或病症的药物中的用途。本发明化合物对A549、MINO、OCI-LY10和TMD-8等肿瘤细胞株具有抗增殖和抑制作用，在Mino皮下异种移植等肿瘤模型中显示出优异的抗肿瘤活性，可应用于治疗与人或动物细胞增殖相关的实体瘤或白血病的药物中。本发明的化合物具有良好的药代动力学特性，可应用于与人或动物细胞增殖相关的实体瘤或白血病或自身免疫性疾病的口服治疗。本发明化合物具有低 hERG 通道阻断特性。
• Selective Bruton's tyrosine kinase inhibitor and use thereof
  申请人：HANGZHOU HERTZ PHARMACEUTICAL CO., LTD.

  公开号：US10711006B2

  公开（公告）日：2020-07-14

  The present invention relates to a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, preparation and use thereof in preparation of a drug. The compound of the present invention has a structure of Formula II or Formula II′: or their optical isomers, or pharmaceutically acceptable salts or solvates; where each Rg is independently H, halogen, —CF2H, —CF3, —CN, C1-C3 alkyl, or C1-C3 alkoxy; n is selected from 0, 1 and 2; Rd is selected from Re is selected from H, CH3, C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH3, C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl; Y1, Y2, Y3 and Y4 are independently selected from C(Rf) and N, and at least one of Y1, Y2, Y3 and Y4 is N, wherein Rf is selected from H, halogen, C1-C3 alkyl, —CF3, and —CF2H.

  本发明涉及一种选择性布鲁顿酪氨酸激酶(BTK)抑制剂化合物、包含该化合物的药物组合物及其制备和在制备药物中的用途。本发明的化合物具有式II或式II'的结构： 或其光学异构体，或药学上可接受的盐或溶剂合物； 其中，每个Rg独立地选自H、卤素、—CF2H、—CF3、—CN、C1-C3烷基或C1-C3烷氧基； n选自0、1和2； Rd选自 Re选自H、CH3、C2-C6烷基、C1-C6氨基烷基和C1-C6氧基烷基，其中CH3、C2-C6烷基、C1-C6氨基烷基和C1-C6氧基烷基进一步被氨基、羟基和C1-C3烷基取代； Y1、Y2、Y3和Y4独立地选自C(Rf)和N，且Y1、Y2、Y3和Y4中至少有一个为N，其中Rf选自H、卤素、C1-C3烷基、—CF3和—CF2H。
• Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development
  作者：Michael A. Letavic、Leah Aluisio、John R. Atack、Pascal Bonaventure、Nicholas I. Carruthers、Christine Dugovic、Anita Everson、Mark A. Feinstein、Ian C. Fraser、Kenway Hoey、Xiaohui Jiang、John M. Keith、Tatiana Koudriakova、Perry Leung、Brian Lord、Timothy W. Lovenberg、Kiev S. Ly、Kirsten L. Morton、S. Timothy Motley、Diane Nepomuceno、Michele Rizzolio、Raymond Rynberg、Kia Sepassi、Jonathan Shelton

  DOI：10.1016/j.bmcl.2010.05.041

  日期：2010.7

  The pre-clinical characterization of novel aryloxypyridine amides that are histamine H-3 receptor antagonists is described. These compounds are high affinity histamine H-3 ligands that penetrate the CNS and occupy the histamine H-3 receptor in rat brain. Several compounds were extensively pro. led pre-clinically leading to the identification of two compounds suitable for nomination as development candidates. (C) 2010 Elsevier Ltd. All rights reserved.